HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: A longitudinal studyHOOPMANN, Markus; NEUMANN, Rainer; TANASALE, Thérese et al.Anticancer research. 2003, Vol 23, Num 2A, pp 1031-1034, issn 0250-7005, 4 p.Conference Paper

Characterization and utilization of two novel anti-erbB-2 monoclonal antibodies in detection of soluble ErbB-2 for breast cancer prognosisLI, P; LI, Y; LI, J. Y et al.Cancer letters. 2003, Vol 193, Num 2, pp 139-148, issn 0304-3835, 10 p.Article

HER-2/neu gene product in serum: An oncoprotein in the diagnosis and therapy of breast carcinomaSCHULZE, Guntram.Anticancer research. 2003, Vol 23, Num 2A, pp 1007-1010, issn 0250-7005, 4 p.Conference Paper

Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancerMOLINA, R; FILELLA, X; ZANON, G et al.Anticancer research. 2003, Vol 23, Num 2A, pp 1043-1050, issn 0250-7005, 8 p.Conference Paper

Immunoprevention and immunotherapy of cancer in ageingPROVINCIALI, Mauro; SMORLESI, Arianna.Cancer immunology and immunotherapy. 2005, Vol 54, Num 2, pp 93-106, issn 0340-7004, 14 p.Article

The Role of Immunohistochemistry in Discriminating Primary From Secondary Extramammary Paget DiseasePERROTTO, John; ABBOTT, Jared J; CEILLEY, Roger I et al.The American journal of dermatopathology. 2010, Vol 32, Num 2, pp 137-143, issn 0193-1091, 7 p.Article

Clinical relevance of HER-2/neu expression in germ-cell testicular tumorsMANDOKY, Laszlo; GECZI, Lajos; BODROGI, Istvan et al.Anticancer research. 2004, Vol 24, Num 4, pp 2219-2224, issn 0250-7005, 6 p.Article

Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopyBLOOM, Kenneth; HARRINGTON, Douglas.American journal of clinical pathology. 2004, Vol 121, Num 5, pp 620-630, issn 0002-9173, 11 p.Article

Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysisMEROLA, R; MOTTOLESE, M; ORLANDI, G et al.European journal of cancer (1990). 2006, Vol 42, Num 10, pp 1501-1506, issn 0959-8049, 6 p.Article

Développement des biothérapies en cancérologie : BiothérapiesJACOT, William; GASCON, Père; JORGENSEN, Christian et al.MT. Médecine thérapeutique. 2007, Vol 13, Num 5, pp 348-352, issn 1264-6520, 5 p.Article

Predictors of response to aromatase inhibitorsANDERSON, Helen; BULUN, Serdar; SMITH, Ian et al.Journal of steroid biochemistry and molecular biology. 2007, Vol 106, Num 1-5, pp 49-54, issn 0960-0760, 6 p.Conference Paper

RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivoURBAN-KLEIN, B; WERTH, S; ABUHARBEID, S et al.Gene therapy (Basingstoke). 2005, Vol 12, Num 5, pp 461-466, issn 0969-7128, 6 p.Article

Overexpression of CC3/TIP30 is associated with HER-2/neu status in breast cancerZHANG, Dao-Hai; LEE LEE WONG; LEE KIAN TAI et al.Journal of cancer research and clinical oncology. 2005, Vol 131, Num 9, pp 603-608, issn 0171-5216, 6 p.Article

Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in miceCOELHO, M; GAUTHIER, P; PUGNIERE, M et al.British journal of cancer. 2004, Vol 90, Num 10, pp 2032-2041, issn 0007-0920, 10 p.Article

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapyBAXEVANIS, Constantin N; SOTIROPOULOU, Panagiota A; SOTIRIADOU, Nectaria N et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 3, pp 166-175, issn 0340-7004, 10 p.Conference Paper

Incidence, mechanism and prognostic value of activated AKT in pancreas cancerSCHLIEMAN, M. G; FAHY, B. N; RAMSAMOOJ, R et al.British journal of cancer. 2003, Vol 89, Num 11, pp 2110-2115, issn 0007-0920, 6 p.Article

HER-2/neu expression : a major prognostic factor in endometrial cancerHETZEL, D. J; WILSON, T. O; KEENEY, G. L et al.Gynecologic oncology (Print). 1992, Vol 47, Num 2, pp 179-185, issn 0090-8258Conference Paper

In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in agingPROVINCIALI, Mauro; BARUCCA, Alessandra; PIERPAOLI, Elisa et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 3, pp 363-371, issn 0340-7004, 9 p.Article

Proteomic characterization of differentially expressed proteins in breast cancer : Expression of hnRNP H1, RKIP and GRP78 is strongly associated with HER-2/neu statusDAOHAI ZHANG; LEE KIAN TAI; LEE LEE WONG et al.Proteomics. Clinical applications (Print). 2008, Vol 2, Num 1, pp 99-107, issn 1862-8346, 9 p.Article

The oncogene HER2 : its signaling and transforming functions and its role in human cancer pathogenesisMOASSER, M. M.Oncogene (Basingstoke). 2007, Vol 26, Num 45, pp 6469-6487, issn 0950-9232, 19 p.Article

Correlation of immunohistochemically detected HER-2/neu (c-erbB-2) with histological stage and perineural invasion in pancreatic cancerTAMIOLAKIS, D; VENIZELOS, I; SIMOPOULOS, C et al.Hepato-gastroenterology. 2004, Vol 51, Num 56, pp 334-337, issn 0172-6390, 4 p.Article

Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivoTHYBUSCH-BERNHARDT, A; AIGNER, A; BECKMANN, S et al.European journal of cancer (1990). 2001, Vol 37, Num 13, pp 1688-1694, issn 0959-8049Article

The association of HER-2/neu Amplification with breast cancer recurrenceCARR, John Alfred; HAVSTAD, Suzanne; ZARBO, Richard J et al.Archives of surgery (Chicago, IL. 1960). 2000, Vol 135, Num 12, pp 1469-1474, issn 0004-0010Article

Tamoxifen up-regulates c-erB-2 expression in oestrogen-responsive breast cancer cells in vitroANTONIOTTI, S; MAGGIORA, P; DATI, C et al.European journal of cancer (1990). 1992, Vol 28, Num 2-3, pp 318-321, issn 0959-8049Conference Paper

A solute protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cellsLIN, Y. J; CLINTON, G. M.Oncogene : (Basingstoke). 1991, Vol 6, Num 4, pp 639-643Article